Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer

Table 1 Summary of compounds entering clinical trials of pancreatic cancer or radiotherapy

Compound	Target	RT	Clinical trial
Rucaparib	PARP	-	A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation (NCT02042378)
Olaparib (AZD2281)	PARP	-	Ph II Olaparib for BRCAness Phenotype in Pancreatic Cancer (NCT02677038)
			Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)(NCT02184195)
			Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer (NCT01296763)
			Efficacy and Safety of PARPi to Treat Pancreatic Cancer (NCT02511223)
			Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer (NCT00515866)
		+	Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC (olaparib) (NCT01562210) Olaparib and Radiotherapy in Inoperable Breast Cancer (NCT02227082)
			Olaparib and Radiotherapy in Head and Neck Cancer (NCT02229656)
			Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer (ORCA-2) (NCT02308072)
BMN673 (Tazaloparib)	PARP	-	Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
			(NCT01286987)
Veliparib (ABT-888)	PARP	-	Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT01585805)
			Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (NCT01233505)
			Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer (NCT01282333)
			Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy (NCT00892736)
			Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT00576654)
			ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (NCT01489865)
		+	A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer (VelGemRad) (NCT01908478)
			A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NCT02412371)
			Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT01386385)
			A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC) (NCT01657799)
			A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases (NCT00649207)
			ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (NCT00770471)
			Pre-Operative Radiation and Veliparib for Breast Cancer (NCT01618357)
Iniparib (BSI-201)	PARP	+	A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (RAPIBE) (NCT01551680)
VX-970 (VE-822)	ATR	+	VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma (NCT02567422)
			VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer (NCT02589522)
AZD6738	ATR	+/-	Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours (Patriot) (NCT02223923)
UCN-01	Chk1	-	UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer (NCT00039403)
			UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer (NCT00045747)
			7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (NCT00031681)
LY2603618	Chk1	-	A Study for Patients With Pancreatic Cancer (NCT00839332)
MK-1775 (AZD1775)	Wee1	-	Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT02194829)
		+	Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas (NCT02037230)
LB-100	PP2A	-	Phase I Study of LB-100 With Docetaxel in Solid Tumors (NCT01837667)
MSC2490484A	DNA-PK	+	Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy (NCT02516813)